5-(4-fluorophenyl)-3-(1-methylethyl)-1-phenyl-1H-pyrazole | 116645-16-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-fluorophenyl)-3-(1-methylethyl)-1-phenyl-1H-pyrazole
• 英文别名: 5-(4-Fluorophenyl)-1-phenyl-3-propan-2-ylpyrazole
• CAS: 116645-16-0
• 化学式: C₁₈H₁₇FN₂
• 分子量: 280.345
• InChiKey: LUWJLPABOKIMMD-UHFFFAOYSA-N

物化性质

• 沸点：
  404.7±33.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(4-fluorophenyl)-3-(1-methylethyl)-1-phenyl-1H-pyrazole 在 N-溴代丁二酰亚胺(NBS) 、 乙酸酐 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 6-<2-<5-(4-fluorophenyl)-3-(1-methylethyl)-1-phenyl-1H-pyrazol-4-yl>ethyl>-5,6-dihydro-2H-pyran-2-one
  参考文献：
  名称：

  Inhibitors of cholesterol biosynthesis. 2. 1,3,5-Trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles

  摘要：

  A series of 1,3,5-trisubstituted pyrazole mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Since previous studies suggested that the 5-(4-fluorophenyl) and 3-(1-methylethyl) substituents afforded optimum potency, attention was focused on variations in position 1 of the pyrazole ring. Biological evaluation of analogues bearing a variety of 1-substituents suggested that, although most substituents were tolerated, none afforded an advantage over phenyl, which exhibited potency comparable to that of compactin in vitro.

  DOI：

  10.1021/jm00163a006
• 作为产物：
  描述：

  1-(4-氟苯基)-4-甲基戊-1,3-二酮 在 sodium hydride 、 sodium iodide 作用下， 以 乙醇 为溶剂， 反应 156.0h， 生成 5-(4-fluorophenyl)-3-(1-methylethyl)-1-phenyl-1H-pyrazole
  参考文献：
  名称：

  Inhibitors of cholesterol biosynthesis. 2. 1,3,5-Trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles

  摘要：

  A series of 1,3,5-trisubstituted pyrazole mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Since previous studies suggested that the 5-(4-fluorophenyl) and 3-(1-methylethyl) substituents afforded optimum potency, attention was focused on variations in position 1 of the pyrazole ring. Biological evaluation of analogues bearing a variety of 1-substituents suggested that, although most substituents were tolerated, none afforded an advantage over phenyl, which exhibited potency comparable to that of compactin in vitro.

  DOI：

  10.1021/jm00163a006

文献信息

• Treating fungal infections with
  申请人：Warner-Lambert Company

  公开号：US04751229A1

  公开（公告）日：1988-06-14

  A method of treating fungal infections in mammals employing 1,3,5-trisubstituted-4- (4-hydroxy-2-oxo-pyran-6-yl)pyrazoles is disclosed.

  本发明揭示了一种使用1,3,5-三取代-4-(4-羟基-2-氧代吡喃-6-基)吡唑治疗哺乳动物真菌感染的方法。
• US4751229A
  申请人：——

  公开号：US4751229A

  公开（公告）日：1988-06-14
• Inhibitors of cholesterol biosynthesis. 2. 1,3,5-Trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles
  作者：D. R. Sliskovic、B. D. Roth、M. W. Wilson、M. L. Hoefle、R. S. Newton

  DOI：10.1021/jm00163a006

  日期：1990.1

  A series of 1,3,5-trisubstituted pyrazole mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Since previous studies suggested that the 5-(4-fluorophenyl) and 3-(1-methylethyl) substituents afforded optimum potency, attention was focused on variations in position 1 of the pyrazole ring. Biological evaluation of analogues bearing a variety of 1-substituents suggested that, although most substituents were tolerated, none afforded an advantage over phenyl, which exhibited potency comparable to that of compactin in vitro.